Whitehawk Therapeutics Secures Option for Five New ADC Programs, Bolstering Pipeline
WHWK has more than doubled off its 52-week low of $1.57.
Summary
Whitehawk Therapeutics has significantly expanded its Antibody Drug Conjugate (ADC) pipeline by securing an option agreement for the CPT113 linker-payload, enabling development of up to five new programs. This follows an 8-K filing earlier today and is a direct execution of the company's strategic pivot to ADC, which was funded by recent private placements totaling $87.5 million. The agreement grants global rights, and the company anticipates multiple Investigational New Drug (IND) submissions within the next 12-24 months. This expansion, utilizing a clinically supported linker-payload, is a highly material development for the small-cap biotech, providing a clear path for future product development and potential value creation.
At the time of this announcement, WHWK was trading at $4.38 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $212.6M. The 52-week trading range was $1.57 to $5.50. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Wiseek News.